Medpage Today on MSN9 个月
Defining and Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...
Medpage Today on MSN9 天
Patisiran Shows Long-Term Benefit in Hereditary ATTR With Polyneuropathy
Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis ...
Yahoo Finance17 天
Polyneuropathy Treatment Market is Projected to Grow at a 4.9% CAGR, Reaching US$ 3.31 ...
Rockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 ...
pharmaphorum6 天
AZ, Ionis get CHMP backing for ATTR polyneuropathy drug
AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines ...
Pharmabiz24 天
argenx’s Vyvdura receives Japanese regulatory approval for adults with chronic ...
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) ...